Navigation Links
Indivumed Study Provides Sound Scientific Basis for a Predictive,Drug Test- Platform

ver 6000 patient-cases, collected with a mean cold ischemia time of less than eight minutes, serves as a resource for Indivumed's cancer research in primary cells and biomarkers as well as for the use of pharmaceutical and biopharma partners.

CONTACT: Hartmut Juhl, M.D., Ph.D., CEO of Indivumed GmbH, T:+49-40-413383-10, F: +49-40-413383-14, E: ; or KevinSullivan, Director, Marketing and Sales of Indivumed, Inc., T:+1-301-588-4650, E: juhl@indivumed.com sullivan@indivumed.com

Web site: http://www.indivumed.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
Other Medicine News:Health News:New Insights Show Ginseng Fights Inflammation 2Health News:Karolinska Institutet Awards Honorary Degree to Feinstein Institute CEO Kevin J. Tracey, MD 2Health News:BUSM researchers find gram-negative rods in two Philippine neonatal intensive care units 2Health News:Major Physician Group Issues Statement in Support of Physician/Industry Relationships 2Health News:Major Physician Group Issues Statement in Support of Physician/Industry Relationships 3Health News:BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting 2Health News:BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting 3Health News:BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting 4